Although there is debate surrounding the definition of metabolic X syndrome in pediatrics and there are few long-term studies of outcomes in children with metabolic syndrome, pediatric metabolic syndrome needs to be on the radar of all pediatricians interested in ensuring a healthy adult life for their patients.
Sjögren’s syndrome is underdiagnosed and seriously impacts the ocular surface and quality of life and places the patient at risk for multisystem involvement. Optometry’s role in identification, diagnosis and collaborative long-term management is an important one. Earlier attention to symptoms leading to diagnosis and collaboration with other health professionals will ensure better quality of life for our patients.
The connection between emotional stress and skin disease is clear enough, an expert says, that it makes sense to recommend stress relief for patients who say their inflammatory skin disease flares under duress.
Lemtrada (alemtuzumab) received FDA approval on November 14, 2014, under fast track designation, for the treatment of patients with relapsing forms of MS.Due to the safety profile, alemtuzumab should generally be reserved for patients who have had an inadequate response to 2 or more drugs indicated for MS.
Although many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.